Get the Stockscreener App
34.90
1.62%
0.61
Exelixis Inc stock is traded at $34.90, with a volume of 1.21M.
It is up +1.62% in the last 24 hours and up +30.70% over the past month.
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
See More
Previous Close:
$34.29
Open:
$34.08
24h Volume:
1.21M
Relative Volume:
0.57
Market Cap:
$9.92B
Revenue:
$2.01B
Net Income/Loss:
$349.99M
P/E Ratio:
123.19
EPS:
0.2833
Net Cash Flow:
$166.29M
1W Performance:
+21.28%
1M Performance:
+30.70%
6M Performance:
+59.11%
1Y Performance:
+65.93%
1-Day Range:
$34.08
$35.15
1-Week Range:
$31.18
$35.15
52-Week Range:
$19.20
$35.15
Exelixis Inc Stock (EXEL) Company Profile
Name
Exelixis Inc
Sector
Industry
Phone
(650) 837-7000
Address
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-19-23 | Initiated | BTIG Research | Buy |
| Dec-15-23 | Initiated | Citigroup | Buy |
| Sep-26-23 | Initiated | H.C. Wainwright | Buy |
| Aug-22-23 | Reiterated | Oppenheimer | Outperform |
| Aug-08-23 | Initiated | SVB Securities | Market Perform |
| Jul-11-23 | Resumed | Morgan Stanley | Equal-Weight |
| May-10-23 | Resumed | Piper Sandler | Overweight |
| Mar-09-23 | Initiated | Wells Fargo | Overweight |
| Jan-26-23 | Initiated | Credit Suisse | Outperform |
| Oct-18-22 | Initiated | JMP Securities | Mkt Outperform |
| Jun-24-22 | Initiated | BMO Capital Markets | Outperform |
| Nov-19-21 | Initiated | Piper Sandler | Overweight |
| Nov-03-21 | Resumed | Jefferies | Buy |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Aug-06-21 | Reiterated | H.C. Wainwright | Buy |
| Jun-15-21 | Initiated | H.C. Wainwright | Buy |
| May-18-21 | Resumed | Goldman | Sell |
| Mar-31-21 | Initiated | Credit Suisse | Outperform |
| Mar-12-21 | Initiated | Wolfe Research | Outperform |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-13-20 | Initiated | SunTrust | Buy |
| Nov-13-19 | Initiated | BofA/Merrill | Buy |
| Mar-18-19 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Sep-17-18 | Initiated | Goldman | Neutral |
| Sep-10-18 | Initiated | Morgan Stanley | Underweight |
| May-11-18 | Reiterated | Needham | Buy |
| Oct-17-17 | Reiterated | Needham | Buy |
| Oct-17-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-16-17 | Reiterated | SunTrust | Buy |
| Sep-22-17 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Sep-12-17 | Reiterated | Needham | Buy |
| Jul-14-17 | Initiated | SunTrust | Buy |
| Mar-31-17 | Initiated | Needham | Buy |
| Mar-16-17 | Initiated | Oppenheimer | Perform |
| Feb-28-17 | Downgrade | Stifel | Buy → Hold |
| Nov-03-16 | Initiated | Deutsche Bank | Buy |
| Oct-10-16 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Sep-15-16 | Reiterated | Stifel | Buy |
View All
Exelixis Inc Stock (EXEL) Latest News
Capital Management Corp VA Increases Position in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Exelixis's SWOT analysis: oncology leader's stock poised for growth - Investing.com
Exelixis Beats on Q3 Earnings and Sales, Raises Annual Outlook - MSN
3 Magnificent Stocks Under $100 to Buy in November - The Motley Fool
New York State Teachers Retirement System Raises Stake in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Exelixis cso sells stock worth $36,486 By Investing.com - Investing.com Australia
Dana Aftab Sells 1,162 Shares of Exelixis, Inc. (NASDAQ:EXEL) Stock - MarketBeat
Exelixis cso sells stock worth $36,486 - Investing.com
Exelixis (NASDAQ:EXEL) Issues Earnings Results, Beats Estimates By $0.04 EPS - MarketBeat
Trend Tracker for (EXEL) - Stock Traders Daily
Exelixis, Inc. Just Recorded A 18% EPS Beat: Here's What Analysts Are Forecasting Next - Yahoo Finance
Exelixis price target raised to $38 from $33 at Truist - MSN
Stephens Investment Management Group LLC Has $98.78 Million Position in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Exelixis: Cabometyx Drives Revenue While Zanzalintinib Emerges As Future Growth Engine - Seeking Alpha
Exelixis, Inc. (NASDAQ:EXEL) Q3 2024 Earnings Call Transcript - Insider Monkey
Exelixis stock hits 52-week high at $31.3 amid robust growth - Investing.com Australia
Exelixis, Inc.'s (NASDAQ:EXEL) Shares Leap 25% Yet They're Still Not Telling The Full Story - Simply Wall St
Earnings call: Exelixis reports solid growth, raises 2024 revenue guidance - Investing.com
Earnings call: Exelixis reports solid growth, raises 2024 revenue guidance By Investing.com - Investing.com UK
Exelixis price target raised to $36 from $33 at Piper Sandler - Yahoo Finance
DekaBank Deutsche Girozentrale Acquires 30,000 Shares of Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Exelixis Inc (EXEL) Q3 2024 Earnings Call Highlights: Strong Rev - GuruFocus.com
Exelixis EVP Jeffrey Hessekiel sells $709,750 in stock - Investing.com
Exelixis stock hits 52-week high at $31.3 amid robust growth By Investing.com - Investing.com South Africa
Royal Bank of Canada Reiterates Outperform Rating for Exelixis (NASDAQ:EXEL) - MarketBeat
Exelixis shares target lifted, retains equal weight on strong Q3 results - Investing.com
Exelixis (NASDAQ:EXEL) Hits New 1-Year High Following Analyst Upgrade - MarketBeat
Stephens Boosts Exelixis (NASDAQ:EXEL) Price Target to $29.00 - MarketBeat
Piper Sandler boosts Exelixis stock target on earnings beat and optimistic revenue outlook - Investing.com UK
FY2024 EPS Estimates for Exelixis Reduced by Leerink Partnrs - MarketBeat
Exelixis stock sees upside with cabozantinib’s patent extension and label expansion - Investing.com UK
Exelixis Reports Strong Q3 2024 Earnings and Pipeline Expansion - TipRanks
Exelixis Inc (EXEL) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
Exelixis Earnings: Raising Valuation on Improved Outlook Thanks to Pipeline Candidate Zanzalintinib - Morningstar
Exelixis Inc (EXEL) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ... - Yahoo Finance
No-Moat Exelixis Focuses on Developing Pipeline to Offset Future Generic Entry for Cabozantinib - Morningstar
Exelixis: Q3 Earnings Snapshot - The Advocate
Exelixis (EXEL) Q3 2024 Earnings Call Transcript - Yahoo! Voices
Exelixis Inc (EXEL) Q3 2024 Earnings: EPS of $0.40 Beats Estimat - GuruFocus.com
Exelixis (EXEL) Reports Q3 Earnings: What Key Metrics Have to Say - Yahoo Finance
Exelixis (EXEL) Q3 Earnings and Revenues Beat Estimates - Yahoo Finance
Exelixis, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
China Universal Asset Management Co. Ltd. Buys 20,641 Shares of Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Q4 Earnings Estimate for Exelixis Issued By Leerink Partnrs - MarketBeat
Assenagon Asset Management S.A. Sells 588,870 Shares of Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Zacks Industry Outlook Highlights Exelixis, Blueprint Medicines, CRISPR, Amicus and Verona Pharma - Yahoo Finance
Exelixis, Inc. (NASDAQ:EXEL) Shares Sold by Allspring Global Investments Holdings LLC - MarketBeat
Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term - Yahoo Finance
Exelixis's SWOT analysis: cabozantinib drives growth amid patent challenges By Investing.com - Investing.com South Africa
Exelixis's SWOT analysis: cabozantinib drives growth amid patent challenges - Investing.com India
Here's Why Exelixis (EXEL) is a Great Momentum Stock to Buy - Yahoo Finance
Exelixis Inc Stock (EXEL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):